My Blue Dots

LEIDEN, Netherlands–(BUSINESS WIRE)– #Adults–Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that it will present at J.P. Morgan’s 43rd Annual Healthcare Conference on Thursday, January 16, 2025. The company’s presentation will begin at 8:30 a.m. PT/11:30 am (Eastern Time). The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with n

DUBLIN–(BUSINESS WIRE)–The “Water Filters Market – Global Outlook & Forecast 2024-2029” report has been added to ResearchAndMarkets.com’s offering. The Water Filters Market was valued at USD 10.05 billion in 2023, and is projected to reach USD 14.97 billion by 2029, rising at a CAGR of 6.87%. Advanced filtration technologies play a crucial role in meeting consumer expectations for ongoing product innovations and enhancements. Leading players such as Pentair, VEOLIA, The 3M Company, and Cu

NEW YORK & DALLAS & PALO ALTO, Calif.–(BUSINESS WIRE)–New Mountain Capital, LLC (“New Mountain”), a leading growth-oriented investment firm with more than $55 billion in assets under management, today announced a definitive agreement to acquire Machinify, Inc. (“Machinify”), a leading provider of artificial intelligence (AI)-powered software transforming healthcare payments. Machinify will become a core part of the company recently formed through the merger of The Rawlings Group (“Rawlings”),

MUNICH & SAN FRANCISCO–(BUSINESS WIRE)–CatalYm today announced the appointment of Scott Clarke as Chief Executive Officer. Mr. Clarke brings over two decades of executive leadership experience in driving company growth, developing products, and shaping and executing transactions in the biopharmaceutical industry. He takes the helm as CatalYm enters a new stage of corporate and clinical development, including the initiation of a broad Phase 2b program for its lead candidate, visugromab, in non

NEW YORK–(BUSINESS WIRE)–Celmatix Therapeutics, a biotechnology company focused on advancing groundbreaking therapeutics for women’s health, has announced its latest drug program, a novel Jun-N-terminal kinase (JNK) inhibitor that targets pain and inflammation. The therapeutic drug candidate, developed using the DNA-Encoded Chemistry Technology (DEC-Tec) platform at the Center for Drug Discovery, Baylor College of Medicine (BCM), aims to address a critical unmet need in first-line treatments